AU2001285334A1 - Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid - Google Patents

Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid

Info

Publication number
AU2001285334A1
AU2001285334A1 AU2001285334A AU8533401A AU2001285334A1 AU 2001285334 A1 AU2001285334 A1 AU 2001285334A1 AU 2001285334 A AU2001285334 A AU 2001285334A AU 8533401 A AU8533401 A AU 8533401A AU 2001285334 A1 AU2001285334 A1 AU 2001285334A1
Authority
AU
Australia
Prior art keywords
cyclooxygenase
migraine
inhibitor
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001285334A
Inventor
Peter Van Patten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001285334A1 publication Critical patent/AU2001285334A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
AU2001285334A 2000-08-29 2001-08-27 Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid Abandoned AU2001285334A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22885100P 2000-08-29 2000-08-29
US60/228,851 2000-08-29
PCT/US2001/026797 WO2002017896A2 (en) 2000-08-29 2001-08-27 Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid

Publications (1)

Publication Number Publication Date
AU2001285334A1 true AU2001285334A1 (en) 2002-03-13

Family

ID=22858798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001285334A Abandoned AU2001285334A1 (en) 2000-08-29 2001-08-27 Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid

Country Status (3)

Country Link
US (1) US8680081B2 (en)
AU (1) AU2001285334A1 (en)
WO (1) WO2002017896A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089798A2 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
US20030207846A1 (en) * 2002-01-07 2003-11-06 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
US8377906B2 (en) * 2004-06-04 2013-02-19 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
EP2335703B1 (en) 2006-06-13 2014-09-24 Ethicon, Incorporated Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
US11696894B2 (en) 2013-12-17 2023-07-11 Celsprin Llc Sequential administration of partitioned absorption aspirin or active aspirin derivative and COX-2 inhibitor
CN104173359B (en) * 2014-09-05 2017-05-03 罗国安 Compound anti-inflammatory and analgesic medicine for lowering side effects of rofecoxib and application of compound anti-inflammatory analgesic medicine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
JPH11507670A (en) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー Treatment of inflammation and inflammation-related diseases with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
TR199802345T2 (en) 1996-05-17 1999-03-22 Merck & Co., Inc. Compositions for once-daily administration in cyclooxygenase-2-mediated diseases.
US5872145A (en) 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
DE69709691T2 (en) 1996-10-21 2002-08-22 Morten Sloth Weidner PHARMACEUTICAL COMPILATIONS WITH PARTHENIUM INTEGRIFOLIUM OR WITH AN EXTRACT OR A COMPONENT THEREOF, USE OF THIS PLANT MATERIAL FOR THE PRODUCTION OF MEDICINE AND A METHOD FOR THE EXTRACT PRODUCTION OF PARTHENIUM INTEGRIFOLIUM
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
SE9703693D0 (en) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
FR2770131A1 (en) 1997-10-27 1999-04-30 Union Pharma Scient Appl Analgesic combinations of a cyclooxygenase-2 inhibitor and acetaminophen or an opiate having synergistic activity
US6136804A (en) 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
CA2348979A1 (en) * 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions
WO2000029022A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
JP2002529499A (en) * 1998-11-13 2002-09-10 イーライ・リリー・アンド・カンパニー How to treat pain
WO2000048583A2 (en) 1999-02-19 2000-08-24 Pozen Inc. Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
CO5190664A1 (en) 1999-06-30 2002-08-29 Pfizer Prod Inc COMBINATION THERAPY FOR THE TREATMENT OF MIGRANA ADMINISTRATION OF A 5HT RECEPTOR, CAFFEINE AND A CYCLLOXYGENASA-2 INHIBITOR
CO5190678A1 (en) 1999-06-30 2002-08-29 Pfizer Prod Inc COMBINED THERAPY FOR THE TREATMENT OF MIGRANA

Also Published As

Publication number Publication date
US8680081B2 (en) 2014-03-25
WO2002017896A2 (en) 2002-03-07
US20030212050A1 (en) 2003-11-13
WO2002017896A3 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
AU2001282886A1 (en) Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001252272A1 (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
AU2001284690A1 (en) Compositions exhibiting synergistic inhibition of the expression and/or activityof cyclooxygenase-2
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
IL159100A0 (en) Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor and a monohydric alcohol
AU2002232575A1 (en) Nutritional composition for improving the efficacy of a lipase inhibitor
AU2003234257A1 (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
WO2001085201A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2002235520A1 (en) Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
IL160087A0 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001285334A1 (en) Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
AUPQ629000A0 (en) Inhibition of fungi
AU2002224550A1 (en) Corrosion inhibitors
IL147363A0 (en) Ppar delta inhibitor for the treatment of cardiovascular diseases
AU7957000A (en) Cyclooxygenase-2 expression inhibitors
WO2002096516A8 (en) Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
AU2002361096A1 (en) Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
AU2003239025A1 (en) Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd
AU2002218084A1 (en) Inhibitors of thromboxane formation and action
AU3721000A (en) Corrosion inhibitor and process
AU2003303625A1 (en) Combination of reboxetine and a cyclooxygenase-2 inhibitor